Estery GilozRan - KAMADA Independent Director

<div class='circular--portrait' style='background:#008000;color: #f8f8f8;font-size:3em;padding-top: 38px;;'>KMD</div>
KMDA -- Israel Stock  

ILA 2,859  236.00  9.00%

  Director
Dr. Estery GilozRan serves as Independent Director at Kamada Ltd. She has served on our board of directors since January 2014 and is an external director within the meaning of the Companies Law. During 2013 Dr. GilozRan was a Visiting Scholar at the New York University in the Department of Accounting, as well as a Visiting Assistant Professor of Finance in the Sy Syms School of Business at the Yeshiva University in New York City. From 2010 to 2014, Dr. GilozRan was also the Head of Accountancy at the Peres Academic Center in the Accounting and Business Administration Department and a lecturer at BenGurion University, teaching courses in finance, taxes and accounting. From 2008 to 2010, Dr. GilozRan was a tax consultant and tax capital investment law adviser at Intel Corporationrationration in Israel. Dr. GilozRan holds a PhD in tax and accounting and an M.B.A. degree, both from Ben Gurion University, and a B.A. degree in Business Management from the Open University. Dr. GilozRan completed her PostDoctorate as Visiting Scholar at New York University in the Leonard N. Stern School of Business in 2014. Dr. GilozRan in a certified public accountant .
Age: 44  Director Since 2014      
(972) 8 9406472  www.kamada.com

KAMADA Management Efficiency

KAMADA has return on total asset (ROA) of 0.0015 % which means that it generated profit of $0.0015 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 0.0019 % meaning that it generated $0.0019 on every $100 dollars invested by stockholders. KAMADA management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 19.30, whereas Return on Average Assets are expected to decline to 0.0015. As of May 24, 2020, Total Assets is expected to decline to about 107 M. In addition to that, Current Assets is expected to decline to about 85 M. The current year Total Liabilities is expected to grow to about 44.1 M, whereas Current Liabilities is expected to decline to about 27 M.
The company has accumulated 5.75 M in total debt with debt to equity ratio (D/E) of 4.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. KAMADA has Current Ratio of 6.02 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Company Summary

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. The company was founded in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 429 people.KAMADA (KMDA) is traded on Tel Aviv Stock Exchange in Israel and employs 429 people.

KAMADA Leadership Team

Pnina Strauss, Vice President - Inhalation programs & IP
Itzhak Krinsky, Director
Barak Bashari, Vice President - Operations
Eran Schenker, Vice President - Medical Director
Tuvia Shoham, Independent Director
Michal Stein, Vice President and Medical Director for Immunology
Shani Dotan, Vice President of Human Resources
Liliana Bar, VP of RandD
Yael Brenner, Vice President - Quality
Abraham Havron, Independent Director
Asaf Frumerman, Director
Ruth Wolfson, Senior Vice President - Scientific Affairs
Shmuel Rubinstein, Director
Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases
Michael Berelowitz, Director
David Tsur, Co-Founder and Deputy Executive Chairman
Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D
Leon Recanati, Chairman of the Board
Gil Efron, CFO, Principal Accounting Officer and Deputy CEO
Jonathan Hahn, Director
Eran Schenkar, Vice President - Medical Director
Gwen Melincoff, Director
Chaime Orlev, Chief Financial Officer
Michal Ayalon, Vice President - Research & Development
Amir London, Chief Executive Officer
Estery GilozRan, Independent Director
Reuven Behar, Director
Eitan Kyiet, Vice President - Business Development
Ziv Kop, Director

Stock Performance Indicators

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page